Virkningen af Noxafil som førstevalgsbehandling til trøske og til fore - byggelse af invasive svampeinfektioner blev desuden fundet at være bevist hos patienter, der får ke - moterapi for akut myelogen leukæmi (AML) eller myelodysplastisk syndrom (MDS) samt til modta - gere af hæmatopoietisk stamcelletransplantation (HSCT), der får høje doser af immundæmpende me - dicin for at modvirke transplantat- mod- vært- reaktion.
It also decided that Noxafil’ s effectiveness had been shown as first-line therapy in oropharyngeal candidiasis and in the prophylaxis of invasive fungal infections in patients receiving chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS), and haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease.